PEPTIDE
Verified ComparisonLast updated: 22 March 2026

KPV vs Thymosin Alpha-1

KPV is a 3-amino-acid fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), studied for immune and barrier function. Thymosin-alpha-1 is a well-established thymic peptide.

Compound A

KPV

Immune

Evidence
3.6/ 5
B

Compound B

Thymosin Alpha-1

Immune

Evidence
3.9/ 5
B+
Editor's note
Thymosin-alpha-1 has established clinical pathways; KPV is a minimal, emerging tripeptide.
CriterionKPVThymosin Alpha-1
Peptide size3 amino acids (tripeptide)28 amino acids
MechanismImmune modulation, barrier supportImmune modulation, thymic
Research development stageEmergingEstablished
Clinical trial dataVery limitedSome approved-context trials
Regulatory pathway (AU)Research-onlyDefined indication pathways

Frequently asked questions

Thymosin-alpha-1 has established clinical pathways; KPV research is emerging.

Want to read the full reviews?